Azzur Group and BioSPEQ Announce Merger - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Azzur Group and BioSPEQ Announce Merger


PTSM: Pharmaceutical Technology Sourcing and Management
Volume 10, Issue 5

Azzur Group and BioSPEQ, a California-based consulting firm, have merged to create a union that will provide consulting services and project resources within the QA, laboratory, clinical, information technology, business processes, manufacturing, operations, and R&D settings.

The Azzur-BioSPEQ merger is the latest in a series of new developments for Azzur Group. Earlier this month, the company acquired Azot and formed Azzur Engineering.

Azzur Group’s main office is located in Willow Grove, PA, with additional offices in Frederick, MD, San Antonio, TX, Cambridge, MA, Cary, NC and Palo Alto, CA. BioSPEQ is headquartered in Irvine, CA with additional offices in Lexington, MA and San Diego, CA.

Source: Azzur Group

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
35%
Breakthrough designations
12%
Protecting the supply chain
35%
Expedited reviews of drug submissions
12%
More stakeholder involvement
6%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
USP Faces New Challenges
Source: PTSM: Pharmaceutical Technology Sourcing and Management,
Click here